These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 7585590

  • 1. Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate.
    DePalatis LR, Frazier KA, Cheng RC, Kotite NJ.
    Cancer Res; 1995 Nov 15; 55(22):5288-95. PubMed ID: 7585590
    [Abstract] [Full Text] [Related]

  • 2. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.
    Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, Miller LS, Houchens D, Cheng R, Kaplan D, Goeckeler W.
    Cancer Res; 1991 Jun 01; 51(11):2889-96. PubMed ID: 1851665
    [Abstract] [Full Text] [Related]

  • 4. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels.
    Arano Y, Fujioka Y, Akizawa H, Ono M, Uehara T, Wakisaka K, Nakayama M, Sakahara H, Konishi J, Saji H.
    Cancer Res; 1999 Jan 01; 59(1):128-34. PubMed ID: 9892197
    [Abstract] [Full Text] [Related]

  • 5. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.
    Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, Bair HJ, Wolf FG, Becker WS, Goldenberg DM.
    Cancer Res; 1995 Sep 01; 55(17):3825-34. PubMed ID: 7641200
    [Abstract] [Full Text] [Related]

  • 6. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points.
    Kobayashi H, Le N, Kim IS, Kim MK, Pie JE, Drumm D, Paik DS, Waldmann TA, Paik CH, Carrasquillo JA.
    Cancer Res; 1999 Jan 15; 59(2):422-30. PubMed ID: 9927057
    [Abstract] [Full Text] [Related]

  • 7. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J.
    Cancer Res; 1993 Aug 15; 53(16):3776-83. PubMed ID: 8339291
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels.
    Uehara T, Koike M, Nakata H, Hanaoka H, Iida Y, Hashimoto K, Akizawa H, Endo K, Arano Y.
    Bioconjug Chem; 2007 Aug 15; 18(1):190-8. PubMed ID: 17226973
    [Abstract] [Full Text] [Related]

  • 9. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [Abstract] [Full Text] [Related]

  • 10. Strategies to reduce renal radioactivity levels of antibody fragments.
    Arano Y.
    Q J Nucl Med; 1998 Dec 15; 42(4):262-70. PubMed ID: 9973841
    [Abstract] [Full Text] [Related]

  • 11. Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenografts.
    Novak-Hofer I, Zimmermann K, Maecke HR, Amstutz HP, Carrel F, Schubiger PA.
    J Nucl Med; 1997 Apr 15; 38(4):536-44. PubMed ID: 9098198
    [Abstract] [Full Text] [Related]

  • 12. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules.
    Schott ME, Milenic DE, Yokota T, Whitlow M, Wood JF, Fordyce WA, Cheng RC, Schlom J.
    Cancer Res; 1992 Nov 15; 52(22):6413-7. PubMed ID: 1423290
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC, Jain M, Moore ED, Wittel UA, Li J, Gwilt PR, Colcher D, Batra SK.
    Eur J Nucl Med Mol Imaging; 2005 Mar 15; 32(3):264-73. PubMed ID: 15791435
    [Abstract] [Full Text] [Related]

  • 14. L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment.
    Kobayashi H, Yoo TM, Kim IS, Kim MK, Le N, Webber KO, Pastan I, Paik CH, Eckelman WC, Carrasquillo JA.
    Cancer Res; 1996 Aug 15; 56(16):3788-95. PubMed ID: 8706025
    [Abstract] [Full Text] [Related]

  • 15. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.
    Clin Cancer Res; 2005 Nov 15; 11(22):8180-5. PubMed ID: 16299250
    [Abstract] [Full Text] [Related]

  • 16. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
    Almqvist Y, Steffen AC, Tolmachev V, Divgi CR, Sundin A.
    Nucl Med Biol; 2006 Nov 15; 33(8):991-8. PubMed ID: 17127172
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G.
    Clin Cancer Res; 1995 Dec 15; 1(12):1447-54. PubMed ID: 9815943
    [Abstract] [Full Text] [Related]

  • 19. Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
    Miao Y, Fisher DR, Quinn TP.
    Nucl Med Biol; 2006 Aug 15; 33(6):723-33. PubMed ID: 16934691
    [Abstract] [Full Text] [Related]

  • 20. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, Yeldell D, Griffiths GL, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.